Mobidiag Granted Patents Covering the Method and related Kit for Detecting Antibiotic Resistant Bacteria

ESPOO, Finland, March 15th, 2017 – Mobidiag Ltd, a Finnish molecular diagnostics company, today announced the issuance of two new patents complementing the Australian Patent n°2010247321 obtained in June 2016: US Patent n°9593381 and Japanese Patent n°6054178 covering a method and a kit for detecting antibiotic resistant bacteria, and more specifically, screening for carbapenemase genes causing carbapenem resistance in bacteria.

“At Mobidiag, we have been developing fast and reliable tests for the detection of infectious diseases, including antibiotic resistance with our Amplidiag® Carba+VRE kit and wider panels soon to come. These new additions to Mobidiag’s intellectual property are key in our global strategy and definitely strengthen our commitment towards the fight against antibiotic resistance, a major worldwide health concern nowadays” said Tuomas Tenkanen, CEO at Mobidiag.

Continue Reading

Mobidiag Announces Release of Amplidiag® Easy, a Proprietary Molecular extraction and PCR Setup System directly from Stool Samples

ESPOO, Finland, January 23rd, 2017  Mobidiag Ltd, a Finnish molecular diagnostics company, today announced the CE-IVD marking of Amplidiag®Easy, a proprietary system allowing nucleic acid extraction and PCR setup directly from stool samples. The Amplidiag® Easy provides users with an automated solution accelerating the sample to result time. As the system runs directly from stool primary sample tubes to PCR setup, no manual intervention is required. Moreover, the Amplidiag® Analyzer software can transfer data directly between the Amplidiag® Easy and PCR instruments simplifying greatly the overall workflow.

Continue Reading

Mobidiag to Offer Amplidiag® Diagnostics Products in South Africa

ESPOO, Finland, January 17th, 2017 – Mobidiag Ltd, a Finnish molecular diagnostics company, today announced that it will offer the Amplidiag®product line in South Africa through a distribution agreement with PerkinElmer® Inc.’s Wallac Oy subsidiary. The Amplidiag® product line includes in vitro diagnostic tests and compatible systems for the detection of gastrointestinal infections.

“Thanks to a large distribution network, our Amplidiag product line is now accessible in most European countries. Our ambition is now to expand our coverage worldwide and towards new markets, starting with Africa. In order to develop ourselves in this specific market, we were looking for a distributor with acknowledged expertise and worldwide leadership in the field of diagnostics. We are then very happy that PerkinElmer agreed to accompany us in this great endeavor,” said Tuomas Tenkanen, CEO at Mobidiag.

Continue Reading

Mobidiag Announces Agency Agreement with YouMed for the Commercialization of its Molecular Diagnostic Product line Amplidiag® in UK

ESPOO, Finland, October 4th, 2016  Mobidiag Ltd, a Finnish molecular diagnostics company, today announced an agreement with YouMed Ltd, bespoke sales, marketing and distribution of high-quality medical technologies, regarding the Amplidiag® product line. Under this agreement, YouMed becomes an agent for commercialization in UK of Amplidiag®product line, in vitro diagnostic tests and compatible system for the detection of gastrointestinal infections.

“For the past months, we have been extending significantly our European distribution network. Making our Amplidiag product line available in the UK was definitely our next strategic step. Besides being clearly a high-value market, I strongly believe that our Amplidiag suite can bring great benefits to UK’s healthcare professionals. With that in mind, we are happy to initiate our partnership with YouMed as our local agent to expand Mobidiag’s market reach and visibility in the UK” said Tuomas Tenkanen, CEO at Mobidiag.

Continue Reading

Mobidiag Signs Agreement with Bioportugal Química Farmacêutica Lda for the Distribution of Amplidiag® Diagnostics Tests in Portugal

ESPOO, Finland, September 26th, 2016  Mobidiag Ltd, a Finnish molecular diagnostics company, today announced an agreement with Bioportugal Química Farmacêutica Lda, expert provider of products for the life science market (diagnostics, pharmaceutical, hospital furniture and equipment), for the distribution of the Amplidiag® product line. Under this agreement Bioportugal becomes the exclusive distributor of Amplidiag®, in vitro diagnostics for gastrointestinal infections, in Portugal.

“For the past months, we have been extending significantly our European distribution network. With a strong background in diagnostics, Bioportugal seemed to be the clear choice to distribute our IVD tests in Portugal. We are then very pleased to expand even more Amplidiag accessibility with the support of Bioportugal” said Tuomas Tenkanen, CEO at Mobidiag.

Continue Reading

Mobidiag Extends Agreement with Biomedica Medizinprodukte GmbH & Co KG for Distribution of Amplidiag® Diagnostics Tests in Central and Eastern Europe (CEE)

ESPOO, Finland, September 5th, 2016  Mobidiag Ltd, a Finnish molecular diagnostics company, today announced an agreement with Biomedica Medizinprodukte GmbH & Co KG, provider of a large panel of medical products for health professionals, medical scientists, and research laboratories, for the distribution of the Amplidiag® product line. Under this new agreement Biomedica Medizinprodukte becomes the exclusive distributor of Amplidiag®, in vitro diagnostics for gastrointestinal infections, in Central and Eastern Europe (Austria, Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Macedonia, Poland, Romania, Serbia, Slovakia, Slovenia).

Continue Reading

Mobidiag Announces Release of Amplidiag® Stool Parasites (CE-IVD), a Multiplex PCR Test to Detect Parasites Directly from Stool Samples

Mobidiag Announces Release of Amplidiag® Stool Parasites (CE-IVD), a Multiplex PCR Test to Detect Parasites Directly from Stool Samples


ESPOO, Finland, August 29th, 2016  Mobidiag Ltd, a Finnish molecular diagnostics company, today announced the launch of its CE-IVD marked Amplidiag® Stool Parasites kit, a molecular test allowing detection of the main diarrhea causing stool parasites: Giardia lamblia, Cryptosporidium spp., Entamoeba histolytica and Dientamoeba fragilis.

Pathogenic protozoa are the main causative agents of parasite-associated gastroenteritis due to their ability to multiply in humans. If not detected and treated in time, they can cause diarrhea and a wide variety of other prolonged symptoms, such as colitis, abdominal discomfort, and nausea, symptoms that compromise quality of human life. As a result, infections caused by stool parasites raise important public health challenges with a strong economic impact globally.

Continue Reading

Mobidiag Secures 15 Million Euros from EIB to Accelerate the Launch of its Novodiag® Platform and Suite of In Vitro Diagnostic Tests

PRESS RELEASE

Mobidiag Secures 15 Million Euros from EIB to Accelerate the Launch of its Novodiag® Platform and Suite of In Vitro Diagnostic Tests

PORI, Finland, July 14th, 2016 – Mobidiag Oy, a Finnish molecular diagnostics company, today announced that it has signed a 15 million euro loan with the European Investment Bank Group. As part of the InnovFin initiative, the loan will allow Mobidiag to finalize and scale up Novodiag®products manufacturing, assay validation and commercialization over the next 3 years. The operation is supported by ‘InnovFin – EU Finance for Innovators’, with the financial backing of the European Union under Horizon 2020 Financial Instruments.

Continue Reading

Mobidiag Announces Distribution Agreement with Isogen Life Science

Raising accessibility to Amplidiag® gastrointestinal diagnostics tests in Europe

ESPOO, Finland, June 23, 2016  Mobidiag Ltd, a Finnish molecular diagnostics company, today announced an agreement with Isogen Life Science, provider of instruments, reagents and consumables for the life sciences market, for the distribution of the Amplidiag® product line. Under this new agreement Isogen becomes the exclusive distributor of Amplidiag®, in vitro diagnostics for gastrointestinal infections, in Belgium, the Netherlands, Luxembourg and Spain.

Continue Reading